{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:55:03Z","timestamp":1788555303888,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd010139","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T00:00:00Z","timestamp":1420848000000}}],"reference-count":48,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010139.pub2","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T00:41:19Z","timestamp":1420850479000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Indacaterol, a once-daily beta<sub>2<\/sub>\n-agonist, versus twice-daily beta<sub>2<\/sub>\n-agonists or placebo for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"James B","family":"Geake","sequence":"first","affiliation":[{"name":"The Prince Charles Hospital; Department of Thoracic Medicine; Chermside Queensland Australia 4032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli J","family":"Dabscheck","sequence":"additional","affiliation":[{"name":"Alfred Hospital; Allergy Immunology and Respiratory Medicine; Melbourne Victoria Australia 3181"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wood-Baker","sequence":"additional","affiliation":[{"name":"University of Tasmania; School of Medicine; Hobart Tasmania Australia 7001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Cates","sequence":"additional","affiliation":[{"name":"St George's, University of London; Population Health Research Institute; Cranmer Terrace London UK SW17 0RE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,10]]},"reference":[{"key":"10.1002\/14651858.CD010139.pub2-BIB0001|cit1","unstructured":"Bateman ED Ferguson GT Barnes N Gallagher N Green Y Henley M Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study European Respiratory Journal 10.1183\/09031936.00200212"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Magnussen H Paggiaro P Jack D Owen R Higgins M Kramer B Bronchodilator treatment with indacaterol once-daily vs formoterol twice-daily in COPD: a 52-week study American Thoracic Society International Conference; 2009 May 15-20 San Diego 2009","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A6184"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0004|cit4","unstructured":"Magnussen H Paggiaro P Jack D Owen R Higgins M Kramer B Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD: a 52-week study European Respiratory Society 19th Annual Congress; 2009 Sep 12-15; Vienna 2009"},{"issue":"2","key":"10.1002\/14651858.CD010139.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease","volume":"182","author":"Donahue","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","article-title":"Efficacy and safety of indacaterol 150mcg once-daily in COPD: a double-blind randomised 12-week study","volume":"10","author":"Feldman","year":"2010","journal-title":"BMC Pulmonary Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010139.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"431B","DOI":"10.1378\/chest.1829807","article-title":"Real-life efficacy of indacaterol and other LABAs in COPD patients in Israel","volume":"145","author":"Izbicki","year":"2014","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD010139.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/15412555.2012.729623","article-title":"Efficacy of Indacaterol 75mcg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies","volume":"9","author":"Gotfried","year":"2012","journal-title":"COPD"},{"issue":"12","key":"10.1002\/14651858.CD010139.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.clinthera.2011.11.009","article-title":"Efficacy and tolerability of indacaterol 75mcg once daily in patients aged > 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12 week studies","volume":"33","author":"Kerwin","year":"2011","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD010139.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/15412555.2012.729623","article-title":"Efficacy of Indacaterol 75mcg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies","volume":"9","author":"Gotfried","year":"2012","journal-title":"COPD"},{"issue":"12","key":"10.1002\/14651858.CD010139.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.clinthera.2011.11.009","article-title":"Efficacy and tolerability of indacaterol 75mcg once daily in patients aged > 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12 week studies","volume":"33","author":"Kerwin","year":"2011","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1440-1843.2011.02107.x","article-title":"Efficacy and safety of indacaterol 150 and 300 mcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week placebo controlled study","volume":"17","author":"Kinoshita","year":"2012","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.rmed.2012.09.002","article-title":"Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population","volume":"106","author":"To","year":"2012","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","article-title":"Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study","volume":"105","author":"Korn","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-94-007-4549-0_4","article-title":"Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients","volume":"756","author":"Mroz","year":"2013","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0017|cit17","first-page":"96","article-title":"Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52-week open-labeled study","volume":"16(2)","author":"To","year":"2011","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Yao W Wang C Zhong N Han X Changgui W Yan X Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study Respirology 2014 231 8 10.1111\/resp.12211","DOI":"10.1111\/resp.12211"},{"issue":"3","key":"10.1002\/14651858.CD010139.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pupt.2010.01.003","article-title":"Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design","volume":"23","author":"Barnes","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD010139.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/15412555.2011.594464","article-title":"Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD","volume":"8","author":"Beeh","year":"2011","journal-title":"COPD"},{"issue":"4","key":"10.1002\/14651858.CD010139.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","article-title":"Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD","volume":"38","author":"Buhl","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD010139.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.10-1830","article-title":"Long-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study","volume":"140","author":"Chapman","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0023|cit23","first-page":"1","article-title":"Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease","volume":"8","author":"Hataji","year":"2012","journal-title":"International Journal of COPD"},{"issue":"6","key":"10.1002\/14651858.CD010139.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.rmed.2011.02.013","article-title":"Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD","volume":"105","author":"Jones","year":"2011","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010139.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/15412555.2011.594464","article-title":"Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD","volume":"8","author":"Beeh","year":"2011","journal-title":"COPD"},{"issue":"12","key":"10.1002\/14651858.CD010139.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.rmed.2010.08.010","article-title":"Indacaterol once-daily is equally effective dosed in the evening or morning in COPD","volume":"104","author":"Magnussen","year":"2010","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD010139.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/15412555.2010.528812","article-title":"Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients","volume":"7","author":"Maele","year":"2010","journal-title":"COPD"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0030|cit30","unstructured":"Novartis Pharmaceuticals A 12-week treatment, multi-centre, randomized, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate\/glycopyrronium bromide in COPD patients with moderate to severe airflow limitation http:\/\/www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/product.jsp?productID=650&diseaseAreaID=9"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0031|cit31","unstructured":"Novartis A 12-week multi-centre randomised open label study evaluating the efficacy and safety of treatment regimens that include onbrez (indacaterol) in patients with moderate to severe COPD (MOVE-ON) http:\/\/www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/displayFile.do?trialResult=9624"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0032|cit32","unstructured":"Novartis Pharmaceuticals A 12-week treatment, multi-centre, randomised, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety and tolerability of indacaterol maleate\/glycopyrronium bromide in COPD patients with moderate to severe airflow limitation http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01712516?term=NCT01712516&rank=1"},{"issue":"9589","key":"10.1002\/14651858.CD010139.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD010139.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0070784","article-title":"Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"8","author":"Chung","year":"August 2013","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.rmed.2012.08.022","article-title":"Indacaterol therapy in patients with COPD not receiving other maintenance treatment","volume":"106","author":"Decramer","year":"2012","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010139.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donahue","year":"2005","journal-title":"COPD"},{"issue":"6","key":"10.1002\/14651858.CD010139.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archinternmed.2010.17","article-title":"Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study","volume":"170","author":"Gershon","year":"2010","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0038|cit38","unstructured":"Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2014_Jan23.pdf"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2466-13-26","article-title":"Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"13","author":"Han","year":"2013","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0040|cit40","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00408-012-9444-2","article-title":"Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review","volume":"191","author":"Jiang","year":"2013","journal-title":"Lung"},{"issue":"3","key":"10.1002\/14651858.CD010139.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD010139.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1465-9921-12-54","article-title":"Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches","volume":"12","author":"Renard","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0044|cit44","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0045|cit45","first-page":"145","article-title":"Comparative efficacy of indacaterol in chronic obstructive pulmonary disease","volume":"7","author":"Ribeiro","year":"2012","journal-title":"International Journal of COPD"},{"issue":"5","key":"10.1002\/14651858.CD010139.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1378\/chest.11-2252","article-title":"Comparison of indacaterol with tiotropium or twice-daily long-acting beta agonists for stable COPD","volume":"145","author":"Rodrigo","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD010139.pub2-BIB0047|cit47","unstructured":"World Health Organization World Health Statistics www.who.int\/whosis\/whostat\/2008\/en\/index.html (accessed 3 September 2012)"},{"issue":"2","key":"10.1002\/14651858.CD010139.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"European Respiratory Journal"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010139.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T18:54:24Z","timestamp":1686164064000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010139.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,10]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010139.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,10]]}}}